|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single SNP analysis showed that genetic variants in SLC30A10, TMEM18, GNPDA2, PRL, TFAP2B, BDNF, MTCH2, FTO, and MC4R were nominally associated with waist circumference (WC), BMI, and risk for abdominal or general obesity in the untreated patients with type 2 diabetes, as well as in the total group of patients with type 2 diabetes (untreated and treated) (p < 0.05).
|
31167208 |
2019 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibodies against ZnT8 are rare in Central-European LADA patients and absent in MODY patients, including those positive for other autoantibodies.
|
30377089 |
2019 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, those with later onset type 1 diabetes had a modestly lower type 1 diabetes genetic risk score (0.268 vs 0.279; p < 0.001 [expected type 2 diabetes population median, 0.231]), a higher islet autoantibody prevalence (GAD-, islet antigen 2 [IA2]- or zinc transporter protein 8 [ZnT8]-positive) of 78% at 13 years vs 62% at 26 years of diabetes duration; (p = 0.02), and were less likely to identify as having type 1 diabetes (79% vs 100%; p < 0.001) vs those with young-onset disease.
|
30969375 |
2019 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies have demonstrated that susceptibility to type 2 diabetes (T2D) is influenced by common polymorphism in the zinc transporter 8 gene SLC30A8, providing novel insight into the role of zinc in diabetes.
|
30756223 |
2019 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function mutations in ZnT8 are associated with protection against type-2 diabetes (T2D), but the protective mechanism is unclear.
|
31591269 |
2019 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A specific genetic variant, rs13266634 (c.973C>T; p.ARG325TRP) in zinc transporter SLC30A8/ZnT8, is associated with protection against Type-2 Diabetes, suggesting it may be actionable for predicting and preventing POHG.
|
31220282 |
2019 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A common ZnT8 gene (<i>SLC30A8</i>) polymorphism increases the risk of type 2 diabetes mellitus (T2DM), and rare mutations may present protective effects.
|
30936916 |
2019 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data position ZnT8 as an appealing target for treatment aimed at maintaining insulin secretion capacity in T2D.
|
31676859 |
2019 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study revealed an unexpected role of ZnT8 in regulating peripheral 5-HT biogenesis and intestinal microenvironment, which might contribute to the increased risk of obesity and type 2 diabetes.
|
30936149 |
2019 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
Solute carrier family 30 member 8 (<i>SLC30A8</i>), encoding the pancreatic zinc transporter ZnT8, is a susceptibility gene for type 2 diabetes (T2D).
|
30181214 |
2018 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our group and others showed that altered ZnT8 function may be involved in the pathogenesis of type 2 diabetes, indicating that the precise control of zinc homeostasis is crucial for maintaining health and preventing various diseases, including lifestyle-associated diseases.
|
29415457 |
2018 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 556 healthy controls and 413 T2DM patients were genotyped for ZnT8 Arg325Trp polymorphism confirming the association of Arg-325 variant with an increased T2DM risk (OR = 1.35 95% C.I: 1.10-1.66; p = 0.0044).
|
30142362 |
2018 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, variants in the SLC30A8 gene, encoding the vesicular/granular zinc transporter ZnT8, are associated with altered insulin release and increased T2D risk while the zinc importer ZIP12 is implicated in pulmonary hypertension.
|
29431830 |
2018 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The non-synonymous single nucleotide polymorphism (SNP) rs13266634 in human zinc transporter 8, ZnT8 (SLC30A8), leads to a R325 variant, which is associated with an increased risk of developing Type 2 Diabetes (T2D).
|
28965566 |
2017 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ZnT8 null mice have a mild phenotype with a slight decrease in glucose tolerance, whereas patients with the ZnT8 R325W polymorphism (rs13266634) have decreased proinsulin staining and susceptibility to T2DM.
|
27899481 |
2017 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In agreement with the human genetic finding that rare loss-of-function mutations in ZnT8 are associated with reduced T2D risk, our results suggested that the common high risk Arg-325 variant is hyperactive, and thus may be targeted for inhibition to reduce T2D risk in the general populations.
|
27875315 |
2016 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Zinc transporter 8 genetic variant SLC30A8 has been associated with postpartum risk of type 2 diabetes among women with gestational diabetes mellitus (GDM).
|
27600066 |
2016 |
|
SLC30A10
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Work of the past decade has identified variants in the human SLC30A8 gene, encoding the zinc transporter ZnT8 which is expressed highly selectively on the secretory granule of pancreatic islet β and α cells, as affecting the risk of Type 2 Diabetes.
|
27262257 |
2016 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in the zinc efflux transport protein ZnT8 have been linked with both type 1 and type 2 diabetes, further supporting an important role for zinc in glucose homeostasis.
|
25969539 |
2015 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
The significant predictive relationships between Zip10, ZnT6, serum glucose and HOMA-IR are preliminary, as is the relationship between HbA1c and ZnT8; nevertheless the observations support an association between Type 2 DM and zinc homeostasis that requires further exploration.
|
25156968 |
2014 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the SLC30A8 gene, encoding the secretory granule zinc transporter 8 (ZnT8), influence type 2 diabetes risk, conceivably by modulating cytosolic Zn(2+) levels.
|
24865615 |
2014 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we introduced two ZnT-8 Type-II diabetes-related mutations into the M. gryphiswaldense MamM protein, a magnetosome-associated CDF transporter essential for magnetite biomineralization within magnetosome vesicles.
|
24819161 |
2014 |
|
SLC30A10
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention.
|
24584071 |
2014 |
|
SLC30A10
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to assess the prevalence of ZnT8 autoantibodies (ZnT8A) in patients with adult-onset diabetes, and to characterize associations between ZnT8A and phenotype, as well as SLC30A8 and HLA-DQB1 genotypes.
|
23194113 |
2013 |
|
SLC30A10
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The first SNP is nonsynonymous (325 Arg>Trp) and maps to the SLC30A8 gene encoding the β-cell-specific ZnT8 zinc transporter, while the second is an intronic SNP in TCF7L2, the strongest known T2D association.
|
22584884 |
2012 |